Road Ahead Still Difficult for Biosimilar Producers in US


Applied Clinical Trials

The FDA has finalized its guidance on interchangeable biosimilars, but the new specifications will still make it a difficult for biosimilar producers looking to make headway in the United States. GlobalData’s Senior Immunology Pharma Analyst, Rose Joachim, weighs in.

See what she has to say here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.